Real-World Outcomes with Avacopan in ANCA-Associated Vasculitis: A Single-Center Experience (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0659; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "98.1% received induction with rituximab- and/or cyclophosphamide-based regimens followed by rituximab maintenance. However, many did not tolerate a full course of therapy, and the observed reduction in steroid exposure compared to standard taper was modest. Comparative analysis with an internal control cohort will further clarify clinical and safety outcomes and help define the role for complement inhibition in AAV."
Clinical • Real-world • Real-world evidence • ANCA Vasculitis • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Renal Disease • Vasculitis
|
|
Ashima Chadha; James L. Chung; Emma R. Schaefer; Sydney Aaron; Sarah Park; Karen A. Laliberte; Orhan Efe; John L. Niles; Ayman Al Jurdi; Harish Shanthanu Seethapathy
|